Vertex expands pipeline as R&D spending surges to $5.1bn in 2024

Overview

Vertex Pharmaceuticals reported a 12% increase in full-year product revenue, driven by strong demand for TRIKAFTA®/KAFTRIO® and the successful global launch of new therapies. In Q4, revenue grew to $2.91bn, with U.S. net product revenue up 17% and international revenue rising 14%. The company also made significant regulatory progress, with the U.S. approval of ALYFTREK™ for cystic fibrosis and JOURNAVX™ for moderate-to-severe acute pain.

CEO Reshma Kewalramani stated: “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch of our fifth CF medicine, ALYFTREK; the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base, disease areas of focus, R&D pipeline, and geographies to continue to deliver long-term value to both patients and shareholders.”

Q4 2024 vs. Q4 2023:

Product revenue for Q4 2024 was $2.91bn (+16% YoY), driven by the continued strength of TRIKAFTA®/KAFTRIO®.
- U.S. net product revenue reached $1.84bn (+17% YoY), supported by higher realized pricing and increased patient demand.
- International net product revenue totaled $1.07bn (+14% YoY), fueled by expansion into new markets.
Net income stood at $913m (-6% vs. Q4 2023), slightly lower compared to the previous year due to higher R&D and commercialization expenses.
Diluted EPS was also on a slight downward trend, reaching the value of $3.50 (-6% YoY).
R&D and SG&A expenses were $1.4bn (GAAP) and $1.2bn (Non-GAAP), increasing as a result of expanded clinical programs.

Full-Year 2024 performance:

Total revenue for full-year 2024 reached $11.02bn (+12% YoY), driven by TRIKAFTA®/KAFTRIO® and expanding patient access.
- U.S. net product revenue totaled $6.68bn (+11% vs. 2023), supported by pricing optimization and higher patient demand.
- International net product revenue was $4.34bn (+13% YoY), fueled by new drug approvals and expanded reimbursement coverage.
GAAP net loss stood at $536m, primarily due to a one-time $4.4bn charge related to the Alpine Immune Sciences acquisition.
Diluted EPS also decreased significantly, from a value of $13.89 for FY2023 to a loss of ($2.08) for FY2024.
Combined GAAP and Non-GAAP R&D and SG&A expenses were $5.1bn (+19% YoY) and $4.2bn (+14% YoY), due to continued R&D investment in support of additional programs that have advanced into Phase 3 clinical development and increased commercial investment to support launches of Vertex’s new therapies globally.
AIPR&D expenses were $4.6bn compared to $527m in 2023 due to $4.4bn of AIPR&D expenses associated with Vertex’s acquisition of Alpine Immune Sciences during 2024.
Cash position at the end of 2024 remained strong at $11.2bn in cash, equivalents, and marketable securities, despite M&A-related outflows and stock buybacks.

For 2025, Vertex anticipates another year of strong growth, supported by new product launches, expanded reimbursement, and continued R&D investment. Total revenue is expected to range between $11.75bn and $12.0bn, driven by CF portfolio growth, increased CASGEVY uptake, and the expansion of JOURNAVX. R&D, AIPR&D, and SG&A expenses are projected between $5.55bn – $5.7bn (GAAP) and $4.9bn – $5.0bn (Non-GAAP), reflecting continued investment in late-stage clinical programs. The effective tax rate is estimated at 20.5% – 21.5% (Non-GAAP). CF business growth will be fueled by expanded patient eligibility, new drug approvals, and global reimbursement initiatives. Additionally, CASGEVY is expected to see increased adoption across multiple regions, while JOURNAVX is projected to experience strong demand as a non-opioid alternative for acute pain management.

The reported results brought little fluctuation to VRTX’s share price this trading week, with it falling by approximately -2.6% after the report was announced.